By Colin Kellaher
Allakos is shedding the bulk of its workforce and scrapping its most advanced product candidate, following the failure of the drug in an early study of patients with the skin condition chronic spontaneous urticaria.
Allakos on Monday said it will pare its staff by 75% to 15 employees and explore strategic alternatives after the drug, AK006, didn't show therapeutic activity in a Phase 1 study.
The San Carlos, Calif., clinical-stage biotechnology company, which ended 2024 with roughly $81 million in cash, equivalents and investments, said it expects to use $34 million to $38 million in cash in restructuring activities to close out AK006 development, and that it will have $35 million to $40 million on hand at the end of June.
Shares of Allakos plunged 71% to 35 cents in premarket trading Monday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 27, 2025 07:45 ET (12:45 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。